The FDA has cleared IND applications for UBT-251 injection, a long-acting triple-targeted glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP)/glucagon receptor agonist developed by The United Bio-Technology (Hengqin) Co. Ltd., a wholly owned subsidiary of The United Laboratories International Holdings Ltd., for adult type 2 diabetes and for overweight or obese subjects.
The calcineurin inhibitor tacrolimus is an immunosuppressive drug frequently used to prevent transplant rejection in solid organ transplant patients. Tacrolimus acts by suppressing T-cell activity within and around the transplanted organ. However, this drug also inhibits T-cell function in the skin, contributing to a high incidence of skin cancer among transplant recipients.
The U.S. Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), has awarded up to $37 million in funding to the Thymus Rejuvenation project, led by Thymmune Therapeutics Inc.
Psoriasis is an autoimmune disorder characterized by abnormal differentiation of keratinocytes and chronic inflammation where current treatments frequently are associated with severe side effects.
Researchers from Longhorn Vaccines & Diagnostics LLC recently presented preclinical data for the novel unconjugated peptide vaccine LHNVD-201, which is being developed as a universal vaccine candidate for protection against different strains of influenza and COVID-19.
Researchers who follow their instincts and achieve slow results while trying to break barriers have little support. They replace it with persistence. This is the story of Katalin Karikó and Drew Weissman. What was once a dream in their minds was later a success. Their work together for decades was essential to achieving mRNA vaccines, and their perseverance was rewarded today with the 2023 Nobel Prize in Medicine.
Shanghai Zhigen Pharmaceutical Technology Co. Ltd. has identified aminoketone compounds with improved chemical stability that are potentially useful for the treatment of depression, post-traumatic stress, obsessive-compulsive disorder, pain and anxiety disorders.
Benzamide compounds acting as UDP-2,3-diacylglucosamine hydrolase (LpxH) (bacterial) inhibitors have been reported in an F. Hoffmann-La Roche Ltd. patent to be useful for the treatment of gram-negative bacterial infections, particularly Klebsiella pneumoniae and Escherichia coli infections.
Research at Baruch S Blumberg Institute has led to the discovery of new diazepine derivatives targeting yellow fever virus nonstructural protein 4B (NS4B) for the treatment of yellow fever virus infections.
RSS
